Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Operating expenses:
Research and development	$ 4,910,409	$ 2,307,022	$ 12,908,679	$ 9,799,811
General and administrative	2,307,946	623,702	4,655,861	1,790,222
Total operating expenses	7,218,355	2,930,724	17,564,540	11,590,033
Other income (expense):
Interest expense	(6,098)	4	(13,537)	(184)
Foreign currency gain (loss)	975,034	(207,542)	2,591,008	741,616
Total other income (expense)	968,936	(207,538)	2,577,471	741,432
Net loss	(6,249,419)	(3,138,262)	(14,987,069)	(10,848,601)
Other comprehensive loss:
Foreign currency translation	(2,940,174)	65,800	(4,926,841)	(1,110,408)
Total comprehensive loss	$ (9,189,593)	$ (3,072,462)	$ (19,913,910)	$ (11,959,009)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (5.29)	$ (2.72)	$ (12.72)	$ (9.40)
Weighted average basic and diluted shares of common stock outstanding (in shares)	1,181,726	1,154,573	1,178,206	1,154,264